Prostaglandin market to cross US$ 1.27 bn by 2035; Liquidia’s Yutrepia okayed for pulmonary hypertension
Prostaglandins are natural fatty acid compounds
produced by the human body. They are made from
FDA approvals drop 8% in 2025, with fewer blockbusters; Brinsupri, Rhapsido make it to first-in-class list
Our
update for new drug approvals by the US Food and Drug Administration (FDA) in
the first half (
FDA approvals drop 24% in H1 2025; GSK’s UTI med, Vertex’s non-opioid painkiller lead pack of first-in-class meds
It has been a turbulent year for the US
Food and Drug Administration (FDA), marked by reduction
US drug shortages reduce 16% YoY in Q1 2025; CNS drugs, antimicrobials face highest scarcities
The pharmaceutical industry in the United States continued to
grapple with drug shortages during th
BMS, J&J, Bayer lead 25,000+ pharma layoffs in 2024; Amylyx, FibroGen, Kronos Bio hit by trial failures, cash crunch
Since 2022, there has been a significant surge in layoffs by pharmaceutical and biotech companies. W
BMS, Bayer, Takeda, Pfizer downsize to combat cost pressures, meet restructuring plans
Over
the last two years, there has been a significant surge in layoffs by
pharmaceutical and biote
Big Pharma bets big on AI’s US$ 148 bn potential to revolutionize healthcare industry
Artificial intelligence (AI) is changing the world and bringing
efficiencies across all industries.
- Privacy policy
- Terms and conditions
- Disclaimers
-
- Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.